Abstract
We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8% and severe neutropenia (ANC <500 cells/μL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3414-3417 |
| Number of pages | 4 |
| Journal | Transplantation proceedings |
| Volume | 45 |
| Issue number | 9 |
| DOIs | |
| State | Published - Nov 1 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Transplantation
Cite this
}
Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients. / Julian, K. G.; Shattahi, E.; Burg, J. E.; Boehmer, J. P.
In: Transplantation proceedings, Vol. 45, No. 9, 01.11.2013, p. 3414-3417.Research output: Contribution to journal › Article
TY - JOUR
T1 - Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients
AU - Julian, K. G.
AU - Shattahi, E.
AU - Burg, J. E.
AU - Boehmer, J. P.
PY - 2013/11/1
Y1 - 2013/11/1
N2 - We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8% and severe neutropenia (ANC <500 cells/μL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.
AB - We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8% and severe neutropenia (ANC <500 cells/μL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.
UR - http://www.scopus.com/inward/record.url?scp=84887056297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887056297&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2013.08.023
DO - 10.1016/j.transproceed.2013.08.023
M3 - Article
C2 - 24182826
AN - SCOPUS:84887056297
VL - 45
SP - 3414
EP - 3417
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 9
ER -